Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles (of the responders).

Elisa Gremese, Gaetano Zizzo, Gianfranco Ferraccioli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

Abatacept (CTLA4Ig), a selective T-cell costimulation modulator, has been approved for the treatment of psoriatic arthritis patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs, but not for those with uncontrolled skin lesions, nor with axial involvement. In this review, we will try to interpret such a differential efficacy of abatacept on the psoriatic arthritis clinical domains, on the basis of its differential effectiveness on the diverse T-cell subsets at different sites. Clinical and biological profiles of abatacept possible responders will be provided.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaImmunotherapy
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • CD28
  • CTLA-4
  • CTLA4Ig
  • T cells
  • abatacept
  • enthesitis
  • obesity
  • psoriasis
  • psoriatic arthritis
  • therapy

Fingerprint Entra nei temi di ricerca di 'Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles (of the responders).'. Insieme formano una fingerprint unica.

Cita questo